2 tables omitted
Each annual birth cohort in the United States comprises approximately
four million infants. Maintaining the gains in childhood vaccination coverage
attained during the 1990s among these children poses an ongoing challenge
for public health. The National Immunization Survey (NIS) is an ongoing survey
that provides estimates of vaccination coverage among children aged 19-35
months on the basis of data for the most recent 12 months for each of the
50 states and 28 selected urban areas. This report presents NIS findings for
2001,* which indicate a substantial nationwide increase in coverage with ≥1
dose of varicella vaccine (VAR), generally steady coverage for other vaccines
nationwide, and wide variability in coverage among the states and urban areas
covered by NIS.
To collect vaccination data for all age-eligible children, NIS uses
a quarterly random-digit–dialing sample of telephone numbers for each
survey area. NIS methodology, including how the responses are weighted to
represent the population of children aged 19-35 months, has been described
previously.1- 2 During 2001,
household interviews were completed for 33,437 children; of these, adequate
health-care provider information was available for 23,551. The response rate
for eligible households for the 78 survey areas was 63.8%. For this report,
NIS data for 2001 were compared with data for 2000.†3
National vaccination coverage with ≥1 dose of VAR increased from
67.8% (95% confidence interval [CI] = ± 0.9%) in 2000 to 76.3% (95%
CI = ± 0.8%) in 2001. Coverage with ≥1 dose of measles, mumps, and
rubella (MMR) vaccine increased from 90.5% (95% CI = ± 0.6%) in 2000
to 91.4% (95% CI = ± 0.6%) in 2001, and coverage with ≥3 doses of
hepatitis B vaccine (HepB) decreased from 90.3% (95% CI = ± 0.6%) in
2000 to 88.9% (95% CI = ± 0.7%) in 2001.
In 2001, estimated vaccination coverage differed substantially among
states. The estimated coverage with the 4:3:1:3:3 series‡ ranged from
81.7% in Rhode Island to 63.2% in New Mexico, a difference of 18.5 percentage
points. Variability among states was lowest for 3 doses of diphtheria and
tetanus toxoids and pertussis vaccine, diphtheria and tetanus toxoids, and
diphtheria and tetanus toxoids and acellular pertussis vaccine (DTP/DT/DTaP)
(9.1 percentage points; range: 89.2%-98.3%) and highest for 1 dose of VAR
(34.1 percentage points; range: 55.8%-89.9%). Variability among the 28 urban
areas was slightly greater than among states. Among the 28 urban areas, the
highest estimate for coverage with the 4:3:1:3:3 series was 79.5% in Jefferson
County, Alabama, and the lowest was 57.7% in Detroit, Michigan, a difference
of 21.8 percentage points.
For the 4:3:1:3:3 series, the magnitude of the disparity between the
highest and lowest estimates for states has been consistent during the preceding
4 years (20.3 percentage points in 1998, 21.4 in 1999, 19.3 in 2000, and 18.5
in 2001) having decreased from 28.1 percentage points in 1997. The decreased
disparity in 1998 compared with 1997 was attributed mostly to more complete
implementation of hepatitis B vaccination in a few states. No state consistently
had either the highest or lowest coverage estimates from year to year.
L Barker, PhD, E Luman, MS, Z Zhao, PhD, P Smith, PhD, R Linkins, PhD,
Data Management Div; J Santoli, MD, L Rodewald, MD, Immunization Svcs Div;
M McCauley, MTSC, Office of the Director, National Immunization Program, CDC.
The findings in this report indicate that among U.S. children aged 19-35
months, coverage with recommended vaccines remains near all-time highs, and
declines observed recently probably are too limited to pose a major public
health risk. Although coverage with recommended vaccines for each new birth
cohort remains high, vigilance is needed to maintain these high levels. Eliminating
the disparity between states and urban areas with the highest and lowest coverage
remains a priority. Should vaccine-preventable disease be introduced in an
area with low coverage, groups of susceptible persons might serve as a reservoir
to transmit disease.
The findings in this report are subject to at least three limitations.
First, NIS is a telephone survey; although statistical weights adjust for
nonresponses and households without telephones, some bias might remain. Second,
NIS relies on provider-verified vaccination histories; incomplete records
and reporting could result in underestimates of coverage. The estimation procedure
assumes that coverage among children whose providers do not respond is similar
to that among children whose providers respond. Finally, although national
level estimates are precise, estimates for states and urban areas should be
interpreted with caution.4
In October 2000, the Advisory Committee on Immunization Practices recommended
that all children aged 2-24 months without contraindications receive 4 doses
of pneumococcal vaccine.5 The first NIS
coverage estimates will be presented next year because the recommendation
applies to all children covered by the 2002 NIS.
Shortages of routinely recommended childhood vaccines, including DTaP,
pneumococcal conjugate vaccine (PCV7), MMR, varicella vaccine, and tetanus
toxoid began in early 2001.6- 9 The
shortages did not affect coverage in 2001 because almost all children included
in the 2001 NIS were eligible to receive recommended vaccines before 2001.
As children potentially affected by the shortages are surveyed by NIS, CDC
will monitor the impact on coverage. The supplies of all vaccines, except
PCV7, have improved. Additional information about the status of the vaccine
shortages is available at http://www.cdc.gov/nip/news/shortages/default.htm.
*For the January-December 2001 reporting period, NIS included children
born during February 1998–May 2000.
†For the January-December 2001 reporting period, NIS included
children born during February 1997–May 1999.
‡Comprises ≥4 doses of diphtheria and tetanus toxoids and
pertussis vaccine, diphtheria and tetanus toxoids, and diphtheria and tetanus
toxoids and acellular pertussis vaccine; ≥3 doses of poliovirus vaccine;
≥1 dose of measles-containing vaccine; ≥3 doses of Haemophilus influenzae type b vaccine; and ≥3 doses of HepB vaccine.
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and
Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early
dhildhood mortality and growth failure data and their association with maternal
Thank you for submitting a comment on this article. It will be reviewed by JAMA editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.